Assertio Holdings (Assertio Holdings) GF Score : 58/100 (As of May. 21, 2024)

View and export this data going back to 1997. Start your Free Trial

What is Assertio Holdings GF Score?

Assertio Holdings has the GF Score of 58, which implies that the company might have Poor future performance potential.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 5/10
2. Profitability Rank : 4/10
3. Growth Rank : 2/10
4. GF Value Rank : 8/10
5. Momentum Rank : 1/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Assertio Holdings might have Poor future performance potential.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Assertio Holdings's GF Score

For the Drug Manufacturers - Specialty & Generic subindustry, Assertio Holdings's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Assertio Holdings's GF Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Assertio Holdings's GF Score distribution charts can be found below:

* The bar in red indicates where Assertio Holdings's GF Score falls into.

Assertio Holdings (NAS:ASRT) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Assertio Holdings GF Score Related Terms

Thank you for viewing the detailed overview of Assertio Holdings's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Assertio Holdings (Assertio Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Assertio Holdings Inc (NAS:ASRT) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 South Saunders Road, Suite 300, Lake Forest, IL, USA, 60045

Website

https://www.assertiotx.com

Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults 18 years of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.

Executives

Daniel A. Peisert	director, officer: President & CEO	C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Paul Schwichtenberg	officer: SVP and CFO	100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Ajay Patel	officer: SVP and CAO	100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Sam Schlessinger	officer: SVP, General Counsel	100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FORREST IL 60045
William Mckee	director
Jeff L Vacirca	director	4747 EXECUTIVE DRIVE, SUITE 510, SAN DIEGO CA 92121
Heather L Mason	director	100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
James L Tyree	director	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064-6400
Crg Partners Iii - Parallel Fund (a) L.p.	10 percent owner	C/O CAPITAL ROYALTY L.P., 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Mark Strobeck	officer: EVP & Chief Operating Officer	460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087
Crg Partners Iii L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Cr Group L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Andrea Heslin Smiley	director	600 LEE ROAD, SUITE 100, WAYNE PA 19087
Megan C. Timmins	officer: SVP, Gen Csl & Sec	600 LEE ROAD, SUITE 100, WAYNE PA 19087
Crg Partners Iii - Parallel Fund B (cayman) L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002